DK3405201T3 - Stabiliseret amorft calciumcarbonat til behandling af neurologiske, muskel- og infertilitetssygdomme eller tilstande - Google Patents

Stabiliseret amorft calciumcarbonat til behandling af neurologiske, muskel- og infertilitetssygdomme eller tilstande Download PDF

Info

Publication number
DK3405201T3
DK3405201T3 DK17741180.8T DK17741180T DK3405201T3 DK 3405201 T3 DK3405201 T3 DK 3405201T3 DK 17741180 T DK17741180 T DK 17741180T DK 3405201 T3 DK3405201 T3 DK 3405201T3
Authority
DK
Denmark
Prior art keywords
muscular
neurological
treatment
conditions
calcium carbonate
Prior art date
Application number
DK17741180.8T
Other languages
English (en)
Inventor
Yosef Ben
Amir Arav
Abraham Shahar
Original Assignee
Amorphical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorphical Ltd filed Critical Amorphical Ltd
Application granted granted Critical
Publication of DK3405201T3 publication Critical patent/DK3405201T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10Carbonates; Bicarbonates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0604Whole embryos; Culture medium therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0608Germ cells
    • C12N5/0609Oocytes, oogonia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0608Germ cells
    • C12N5/061Sperm cells, spermatogonia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0608Germ cells
    • C12N5/0612Germ cells sorting of gametes, e.g. according to sex or motility
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/05Inorganic components
    • C12N2500/10Metals; Metal chelators
    • C12N2500/12Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
    • C12N2500/14Calcium; Ca chelators; Calcitonin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00Cells related to new breeds of animals
    • C12N2517/10Conditioning of cells for in vitro fecondation or nuclear transfer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
DK17741180.8T 2016-01-18 2017-01-17 Stabiliseret amorft calciumcarbonat til behandling af neurologiske, muskel- og infertilitetssygdomme eller tilstande DK3405201T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662279843P 2016-01-18 2016-01-18
US201662279845P 2016-01-18 2016-01-18
US201662279844P 2016-01-18 2016-01-18
US201662376428P 2016-08-18 2016-08-18
PCT/IL2017/050059 WO2017125918A1 (en) 2016-01-18 2017-01-17 Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions

Publications (1)

Publication Number Publication Date
DK3405201T3 true DK3405201T3 (da) 2023-08-21

Family

ID=59361712

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17741180.8T DK3405201T3 (da) 2016-01-18 2017-01-17 Stabiliseret amorft calciumcarbonat til behandling af neurologiske, muskel- og infertilitetssygdomme eller tilstande

Country Status (12)

Country Link
US (2) US10758566B2 (da)
EP (2) EP4257141A3 (da)
JP (3) JP6873389B2 (da)
KR (2) KR102828392B1 (da)
CN (2) CN118787660A (da)
AU (2) AU2017208953B2 (da)
CA (2) CA3011667C (da)
DK (1) DK3405201T3 (da)
ES (1) ES2952537T3 (da)
IL (1) IL260548B2 (da)
RU (1) RU2757419C2 (da)
WO (1) WO2017125918A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2739563C2 (ru) * 2015-06-04 2020-12-25 Аморфикал Лтд. Аморфный карбонат кальция, стабилизированный полифосфатами или бисфосфонатами
AU2017210259B2 (en) 2016-01-18 2022-11-03 Amorphical Ltd. Stabilized amorphous calcium carbonate as a supplement for cell culture media
US20220152094A1 (en) * 2016-01-18 2022-05-19 Amorphical Ltd. Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions
JP7152785B2 (ja) 2016-10-25 2022-10-13 アモーフィカル リミテッド. 白血病治療のための非晶質炭酸カルシウム
JP7794434B2 (ja) * 2019-07-23 2026-01-06 アモーフィカル リミテッド. 運動能力を向上させるための非晶質炭酸カルシウム
EP4117685A4 (en) * 2020-03-11 2024-03-20 Amorphical Ltd. AMORPHOUS CALCIUM CARBONATE FOR THE TREATMENT OF ACIDOSIS
IT202200010583A1 (it) * 2022-05-23 2023-11-23 Neilos S R L “Composizione nutraceutica o farmaceutica per l’infertilità maschile”
IT202200010592A1 (it) * 2022-05-23 2023-11-23 Neilos S R L “Composizione nutraceutica o farmaceutica per l’infertilità maschile”

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757017A (en) 1984-09-14 1988-07-12 Mcw Research Foundation, Inc. In vitro cell culture system
EP1048724A1 (en) * 1999-04-27 2000-11-02 Transgene S.A. Human myoblast cell lines and their uses
US7695426B2 (en) * 2003-08-20 2010-04-13 Biological Resources Pty Ltd Methods for enhancing viability
WO2005026324A2 (en) * 2003-09-08 2005-03-24 The Board Of Regents Of The University Of Texas System Method and composition for enhancing in vitro embryo development by supplementing culture medium with prostaglandin or a prostaglandin analog
AU2005247198B2 (en) 2004-05-26 2011-09-22 Ben-Gurion University Of The Negev Research And Development Authority Orally-administrable compositions comprising stable amorphous calcium carbonate
US20080039531A1 (en) * 2005-06-13 2008-02-14 Alfred Stracher Compositions, and kits comprising targeted aldehyde or acetal protease inhibitor compounds for treating muscle disorders
RU2462458C2 (ru) * 2006-02-10 2012-09-27 Байомарин Ига Лимитед Лечение миодистрофии дюшена
IL178495A (en) * 2006-10-05 2014-12-31 Univ Ben Gurion Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
ES2528901T3 (es) * 2007-10-22 2015-02-13 Amorphical Ltd. Carbonato de calcio amorfo estable que comprende aminoácidos fosforilados, péptidos fosforilados sintéticos y proteínas gastrolíticas
WO2013088440A1 (en) * 2011-12-13 2013-06-20 Amorphical Ltd. Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
RU2637019C2 (ru) 2012-08-07 2017-11-29 Аморфикал Лтд. Способ получения стабилизированного аморфного карбоната кальция
HK1215192A1 (zh) * 2013-02-11 2016-08-19 艾玛菲克有限公司 用於加速骨生长的无定形碳酸钙
JP6860473B2 (ja) 2014-07-31 2021-04-14 アモーフィカル リミテッド. 非晶質炭酸カルシウムの液体および半固体の非水性製剤
RU2739563C2 (ru) 2015-06-04 2020-12-25 Аморфикал Лтд. Аморфный карбонат кальция, стабилизированный полифосфатами или бисфосфонатами
AU2017210259B2 (en) 2016-01-18 2022-11-03 Amorphical Ltd. Stabilized amorphous calcium carbonate as a supplement for cell culture media

Also Published As

Publication number Publication date
CN118787660A (zh) 2024-10-18
EP3405201B1 (en) 2023-05-17
AU2017208953B2 (en) 2022-11-03
JP7507506B2 (ja) 2024-06-28
US20200345764A1 (en) 2020-11-05
JP2019501947A (ja) 2019-01-24
IL260548B2 (en) 2024-04-01
RU2018129457A (ru) 2020-02-20
CN108778296A (zh) 2018-11-09
AU2022252805A1 (en) 2022-11-10
EP3405201A1 (en) 2018-11-28
RU2018129457A3 (da) 2020-10-21
JP2021105026A (ja) 2021-07-26
BR112018014520A2 (pt) 2018-12-11
AU2017208953A1 (en) 2018-09-06
CN108778296B (zh) 2024-07-09
EP4257141A2 (en) 2023-10-11
IL260548A (da) 2018-09-20
US11207347B2 (en) 2021-12-28
JP6873389B2 (ja) 2021-05-19
AU2022252805B2 (en) 2025-03-13
JP7190760B2 (ja) 2022-12-16
CA3239809A1 (en) 2017-07-27
EP4257141A3 (en) 2023-11-22
RU2757419C2 (ru) 2021-10-15
KR20250114395A (ko) 2025-07-29
US20190030068A1 (en) 2019-01-31
WO2017125918A1 (en) 2017-07-27
CA3011667A1 (en) 2017-07-27
US10758566B2 (en) 2020-09-01
IL260548B1 (en) 2023-12-01
CA3011667C (en) 2024-09-17
EP3405201A4 (en) 2019-06-26
KR102828392B1 (ko) 2025-07-02
ES2952537T3 (es) 2023-11-02
JP2023029914A (ja) 2023-03-07
KR20180109941A (ko) 2018-10-08

Similar Documents

Publication Publication Date Title
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
IL258402A (en) Electroporation for obesity or diabetes treatment
DK3405201T3 (da) Stabiliseret amorft calciumcarbonat til behandling af neurologiske, muskel- og infertilitetssygdomme eller tilstande
DK3407889T3 (da) Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
DK3478679T3 (da) 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
IL269174A (en) Methods for treating complement-mediated diseases and disorders
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3789501T3 (da) Fremgangsmåde til diagnosticering, behandling og forebyggelse af parkinsons sygdom
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3609529T3 (da) Rna til behandling af autoimmune sygdomme
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3503890T3 (da) Anvendelse af pridopidin til behandling af dystonier
DK3624796T3 (da) Pyrrolopyridin.anilinforbindelser til behandling af hudlidelse
CL2018001502A1 (es) Procedimiento para el tratamiento de efluente acuoso.
DK3612208T5 (da) Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
DK3261661T3 (da) Menotropin til behandling af infertilitet
LT3377094T (lt) Susilpninto virulentiškumo bakterijos, skirtos piktybinių solidinių navikų gydymui
DK3724173T3 (da) Forbindelser til behandling af neuromuskulære lidelser
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3532064T3 (da) Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner
DK3624795T3 (da) Kondenserede, heteroaromatiske anilinforbindelser til behandling af hudforstyrrelser
DK3529234T3 (da) Forbindelser, fremgangsmåde til opnåelse af forbindelserne, farmaceutisk sammensætning, anvendelse af forbindelserne og fremgangsmåde til behandling af psykiatriske lidelser og/eller søvnforstyrrelser
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3432895T3 (da) Blodpladepelletlysat til anvendelse til behandling af neurologiske forstyrrelser